According to filings with the U.S. Securities and Exchange Commission, Octagon Therapeutics is raising up to $12,410,030.00 in new funding. Sources indicate that as part of senior management President and Chief Operating Officer, Isaac Stoner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Octagon Therapeutics
Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease. Octagon’s team is deeply committed to developing new medicines for diseases with unmet clinical need. The underlying discovery approach can have enormous impact in neglected drug development areas, including orphan autoimmune indications. The management team includes highly skilled scientists, clinicians, and entrepreneurs with decades of research experience and deep expertise in drug development.  The scientific team is growing and continues to add top research talent.

To learn more about Octagon Therapeutics, visit http://www.octagontherapeutics.com/

Contact:
Isaac Stoner, President and Chief Operating Officer
857-488-3417
https://www.linkedin.com/in/isaacstoner/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.